Article
Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-α2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 trial.
Antiviral therapy - 1 Jan 2013
Ogert Robert A, Howe John A, Vierling John M, Kwo Paul Y, Lawitz Eric J, McCone Jonathan, Schiff Eugene R, Pound David, Davis Mitchell N, Gordon Stuart C, Ravendhran Natarajan, Rossaro Lorenzo, Jacobson Ira M, Ralston Robert, Chaudhri Eirum, Qiu Ping, Pedicone Lisa D, Brass Clifford A, Albrecht Janice K, Barnard Richard J O, Hazuda Daria J, Howe Anita Y M
Abstract excerpt
BACKGROUND: Resistance to direct-acting antivirals represents a new challenge in the treatment of chronic hepatitis C. METHODS: SPRINT-1 was a randomized study of treatment-naive patients with genotype (G) 1 hepatitis C infection (n=595) that evaluated the safety and efficacy of boceprevir (BOC) when added to pegylated interferon-α2b plus ribavirin (PR). Plasma samples collected at protocol-specified visits were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.